Cypherpunk Technologies, having pivoted from its biotech origins, continues to build a unique dual business model integrating deep privacy-focused blockchain asset holdings with innovative oncology R&D through its subsidiary Leap Therapeutics. The latest quarterly filings reveal ongoing deployment in digital asset treasury management centered on Zcash, alongside clinical-stage progress on sirexatamab, a monoclonal antibody in oncology. Despite facing typical biotech development risks and crypto market volatility, Cypherpunk’s fortified liquidity and clear milestone targets underscore its ambition to merge two highly specialized yet complementary technology fields.